PURPOSE OF REVIEW: The aim of this review is to perform a critical analysis of all completed studies evaluating the role of anticoagulant agents in improving survival in @entity1 with @entity5 . Furthermore, the rationale for testing anticoagulant drugs in this setting, and the recent basic research studies providing new evidence for a link between tissue malignant transformation of tissues and hemostatic proteins, are also briefly reviewed. RECENT FINDINGS: Four prospective randomized clinical studies to test the impact of low-molecular-weight heparin on mortality in @entity5 @entity1 have been published. The results suggest a benefit from treatment, particularly in @entity1 with @entity66 . Inhibition of specific clotting pathways by anticoagulants may be hypothesized, particularly those involved in the malignant behavior of tissues. In the same vein, a direct action of anticoagulants on mechanisms of @entity5 growth and progression can be considered. SUMMARY: An antineoplastic effect of anticoagulant agents has often been suggested. Heparin and @entity2067 antagonists have both been tested in this context. Heparin has been more extensively studied. Data from clinical trials of thromboprophylaxis in @entity5 @entity1 have suggested that heparin may have beneficial effects on survival in these @entity1 , with a major role for low-molecular-weight heparin compared with unfractionated heparin. Recently, the results of new prospective randomized clinical trials to evaluate the effect of low-molecular-weight heparin on @entity5 survival have become available. The published data look promising and provide an important step forward in the research knowledge in this field.

Effect of anticoagulant drugs in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['nonadvanced disease']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
